Explore: Seed · United Kingdom
Healome Therapeutics
seed · 🇬🇧 Birmingham, United Kingdom · Founded 2021 · 1-10 employees
University of Birmingham spinout developing a proprietary eye-drop matrix platform for ocular surface diseases. Healome Therapeutics is a healthtech and deeptech startup based in Birmingham, United Kingdom, founded 2021, at seed stage, with $2.7M raised to date.
Healome Therapeutics is tracked live on Scout, Fusion42's database of newly funded startups — its profile updates as new rounds, backers and Wire analysis land.
Total raised
$2.7M
Stage
seed
Business model
transactional
Key differentiator
Its eye-drop matrix technology uniquely behaves as a liquid upon application but self-structures into a customizable, clear, protective gel that enhances drug retention and promotes healing for 2–8 hours.
Target customer
Pharmaceutical companies developing ocular therapeutics and healthcare providers treating ocular surface diseases
Sectors
Funding rounds
seed
8 May 2025
Led by Empirical Ventures
With DEBRA Research, Cure EB, Oshen Bio and SFC Capital
Key investors
Empirical Ventures, SFC Capital, DEBRA Research, Cure EB, Oshen Bio, Innovate UK, Medical Research Council, University of Birmingham
Notable achievements
- Closed an oversubscribed £2 million seed round led by Empirical Ventures in July 2026
- Winner of PITCH @ Med-Tech Expo 2025
- Targeting first-in-human phase 1 trials in 2027
- Raised over £3.2 million in prior grant and funding from Innovate UK, Medical Research Council, and SFC Capital
Backed by
Frequently asked questions
- What does Healome Therapeutics do?
- University of Birmingham spinout developing a proprietary eye-drop matrix platform for ocular surface diseases.
- Where is Healome Therapeutics based?
- Healome Therapeutics is based in Birmingham, United Kingdom, founded in 2021.
- How much has Healome Therapeutics raised?
- Healome Therapeutics has raised $2.7M in tracked funding and is currently at the seed stage.
- Who has invested in Healome Therapeutics?
- Investors in Healome Therapeutics include Empirical Ventures, SFC Capital, DEBRA Research, Cure EB, Oshen Bio, Innovate UK, Medical Research Council and University of Birmingham.